M&A: Eton Pharmaceuticals, Inc.

Form Type: 8-K

Filing Date: 2025-01-03

Corporate Action: Acquisition

Type: New

Accession Number: 000143774925000109

Comments: On December 31, 2024, Eton Pharmaceuticals, Inc. acquired Galzin® (zinc acetate) from Teva Pharmaceuticals USA, Inc. Galzin® is the only FDA-approved zinc treatment for maintenance therapy in patients with Wilson Disease who were initially treated with a chelating agent. Eton is set to take over the commercialization of Galzin® in the U.S. in the first quarter of 2025 and will employ its metabolic sales force to support healthcare professionals treating Wilson Disease. Additionally, Eton acquired European rights to the product, which is marketed as Wilzin® by a third party, with Eton continuing to supply the product while the third party oversees commercialization efforts. The total purchase price for Galzin® was $7.0 million at closing, with an additional $0.2 million paid for product inventory. Eton will also pay a 10% royalty on U.S. net sales to Teva for a duration lasting until the tenth anniversary of the first commercial sale in the U.S.

Document Link: View Document